CL2017002196A1 - Vacuna recombinante contra enteropatía proliferativa en animales. - Google Patents

Vacuna recombinante contra enteropatía proliferativa en animales.

Info

Publication number
CL2017002196A1
CL2017002196A1 CL2017002196A CL2017002196A CL2017002196A1 CL 2017002196 A1 CL2017002196 A1 CL 2017002196A1 CL 2017002196 A CL2017002196 A CL 2017002196A CL 2017002196 A CL2017002196 A CL 2017002196A CL 2017002196 A1 CL2017002196 A1 CL 2017002196A1
Authority
CL
Chile
Prior art keywords
vaccine against
recombinant
animals
proteins
recombinant vaccine
Prior art date
Application number
CL2017002196A
Other languages
English (en)
Inventor
Alonso Jorge Toledo
Ramos Oliberto Sanchez
Segui Raquel Montesino
Garrido Alvaro Rafael Ruiz
Mella Nicolas Gutierrez
Villar Omar Farnos
Gajardo Angela Hidalgo
Delgado Eduardo Ramos
San Martin Marcelo Cortes
Original Assignee
Univ De Concepción
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Concepción filed Critical Univ De Concepción
Priority to CL2017002196A priority Critical patent/CL2017002196A1/es
Publication of CL2017002196A1 publication Critical patent/CL2017002196A1/es
Priority to US16/643,147 priority patent/US11661444B2/en
Priority to CN201880070346.5A priority patent/CN111655282A/zh
Priority to BR112020004003-7A priority patent/BR112020004003A2/pt
Priority to PCT/CL2018/050073 priority patent/WO2019041056A1/es
Priority to MX2020002283A priority patent/MX2020002283A/es
Priority to ARP180102446A priority patent/AR113253A1/es
Priority to UY0001037862A priority patent/UY37862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>Vacuna recombinante contra Lawsonia intracellularis basada en una variante quimerica sintética recombinante de proteínas de membrana e invasinas de dicha bacteria, Adicionalmente, se divulgan secuencias nucleotidicas sintéticas que codifican dichas variantes proteicas, proteínas recombinantes como tales, un casete de expresión de dichos antigenos sintéticos proteicos, una célula transformada y un método para Ia producción de dichos antigenos, demostrando su antigenicidad y potencial de protección al patógeno Lawsonia intracellularis.</p>
CL2017002196A 2017-08-30 2017-08-30 Vacuna recombinante contra enteropatía proliferativa en animales. CL2017002196A1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CL2017002196A CL2017002196A1 (es) 2017-08-30 2017-08-30 Vacuna recombinante contra enteropatía proliferativa en animales.
US16/643,147 US11661444B2 (en) 2017-08-30 2018-08-28 Recombinant vaccine against proliferative enteropathy in animals
CN201880070346.5A CN111655282A (zh) 2017-08-30 2018-08-28 一种对抗动物增生性肠病的重组疫苗
BR112020004003-7A BR112020004003A2 (pt) 2017-08-30 2018-08-28 vacina recombinante contra enteropatia proliferativa em animais
PCT/CL2018/050073 WO2019041056A1 (es) 2017-08-30 2018-08-28 Vacuna recombinante contra la enteropatía proliferativa en animales
MX2020002283A MX2020002283A (es) 2017-08-30 2018-08-28 Vacuna recombinante contra la enteropatia proliferativa en animales.
ARP180102446A AR113253A1 (es) 2017-08-30 2018-08-29 Vacuna recombinante contra la enteropatía proliferativa en animales
UY0001037862A UY37862A (es) 2017-08-30 2018-08-29 Vacuna recombinante contra la enteropatía proliferativa en animales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2017002196A CL2017002196A1 (es) 2017-08-30 2017-08-30 Vacuna recombinante contra enteropatía proliferativa en animales.

Publications (1)

Publication Number Publication Date
CL2017002196A1 true CL2017002196A1 (es) 2017-11-17

Family

ID=61147202

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002196A CL2017002196A1 (es) 2017-08-30 2017-08-30 Vacuna recombinante contra enteropatía proliferativa en animales.

Country Status (8)

Country Link
US (1) US11661444B2 (es)
CN (1) CN111655282A (es)
AR (1) AR113253A1 (es)
BR (1) BR112020004003A2 (es)
CL (1) CL2017002196A1 (es)
MX (1) MX2020002283A (es)
UY (1) UY37862A (es)
WO (1) WO2019041056A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023211963A2 (en) * 2022-04-25 2023-11-02 Sivec Biotechnologies, Inc. Chimeric invasin system
CN118909105A (zh) * 2024-07-04 2024-11-08 华中农业大学 一株杂交瘤细胞的制备及其应用
CN119044482B (zh) * 2024-08-08 2025-11-18 华中农业大学 一种检测胞内劳森菌抗体的阻断elisa试剂盒和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512851A (ja) 2000-11-10 2004-04-30 アグリカルチュア　ビクトリア　サービシーズプロプライエトリー　リミティッド ラウソニア種による感染を処置する新規な治療用組成物
ES2360225T3 (es) 2000-12-20 2011-06-02 Intervet International Bv Vacuna contra lawsonia intracellularis.
JP2009509496A (ja) 2005-04-28 2009-03-12 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ローソニアイントラセルラリスの免疫学的タンパク
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
JP2012506858A (ja) 2008-10-23 2012-03-22 インターベット インターナショナル ベー． フェー． Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓワクチン

Also Published As

Publication number Publication date
UY37862A (es) 2019-03-29
MX2020002283A (es) 2020-10-05
US11661444B2 (en) 2023-05-30
AR113253A1 (es) 2020-03-11
BR112020004003A2 (pt) 2020-09-01
CN111655282A (zh) 2020-09-11
US20210221855A1 (en) 2021-07-22
WO2019041056A1 (es) 2019-03-07

Similar Documents

Publication Publication Date Title
BR112018004965A2 (pt) domínios de superfamìlia de imunoglobulina variante ajustàvel
CO2017006651A2 (es) Anticuerpos anti-c5
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
MX383150B (es) Receptores quiméricos de antígeno que tienen como diana a cd-19.
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
AR096869A1 (es) Neurotoxinas catiónicas
BR112016027196A2 (pt) cepa bacteriana gram-negativa recombinante, vetor, método para liberar uma proteína heteróloga em uma célula eucariótica, método para purificar uma proteína heteróloga e uso de uma cepa bacteriana gram-negativa recombinante
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
BR112017025954A2 (pt) apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
BR112015000585A8 (pt) método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante
UY35366A (es) ?genes de toxina y métodos para su uso?.
MX350306B (es) Vacuna y metodos para reducir una infeccion por campylobacter.
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
AR090668A1 (es) Anticuerpo anti-adamts-5, derivados y usos del mismo
MX2017005925A (es) Metodos de producción de proteínas de cadena doble en bacterias.
PH12015502353B1 (en) Fusion polypeptides and vaccines
BR112016016103A2 (pt) Composição de antígenos micobacterianos
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
CL2017002196A1 (es) Vacuna recombinante contra enteropatía proliferativa en animales.
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
NZ725212A (en) Group a streptococcus vaccine